Insulin use and cancer risk in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies

Diabetes and Metabolism

Volumn 38, Issue 6, 2012, Pages 485-506

  Colmers, I N ^a   Bowker, S L ^a   Tjosvold, L A ^a   Johnson, J A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cancer; Glargine; Insulin; Meta analysis; Pharmacoepidemiology; Review; Systematic review; Type 2 diabetes

Indexed keywords

INSULIN; INSULIN GLARGINE;

ADVERSE OUTCOME; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; BRONCHUS CANCER; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; COLORECTAL CANCER; DRUG SAFETY; DRUG USE; ESOPHAGUS CANCER; HODGKIN DISEASE; HUMAN; INSULIN TREATMENT; KIDNEY CANCER; LEUKEMIA; LIVER CANCER; LUNG CANCER; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OVARY CANCER; PANCREAS CANCER; PLEURA CANCER; PROSTATE CANCER; REVIEW; SIDE EFFECT; SKIN CANCER; STOMACH CANCER; SYSTEMATIC REVIEW; TESTIS CANCER; THYROID CANCER; UTERINE CERVIX CANCER; UTERINE TUBE CARCINOMA;

CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN; NEOPLASMS; RISK FACTORS;

EID: 84870673443     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2012.08.011     Document Type: Review

References (50)

1. Vigneri P., Frasca F., Sciacca L., Pandini G., Vigneri R. Diabetes and cancer. Endocr Relat Cancer 2009, 16:1103-1123.
2. Nicolucci A. Epidemiological aspects of neoplasms in diabetes. Acta Diabetologica 2010, 47:87-95.
3. Giovannucci E., Harlan D.M., Archer M.C., Bergenstal R.M., Gapstur S.M., Habel L.A., et al. Diabetes and cancer: a consensus report. Diabetes Care 2010, 33:1674-1685.
4. Tabák A.G., Jokela M., Akbaraly T.N., Brunner E.J., Kivimäki M., Witte D.R. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 2009, 373:2215-2221.
5. Johnson J.A., Carstensen B., Witte D., Bowker S.L., Lipscombe L., Renehan A.G., et al. Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia 2012, 55:1607-1618.
6. Johnson J.A., Bowker S.L. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 2011, 54:25-31.
7. Renehan A.G., Yeh H.C., Johnson J.A., Wild S.H., Gale E.A.M., Møller H., et al. Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia 2012, 55:1619-1632.
8. Decensi A., Puntoni M., Goodwin P., Cazzaniga M., Gennari A., Bonanni B., et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prevent Res 2010, 3:1451-1461.
9. Colmers I.N., Bowker S.L., Majumdar S.R., Johnson J.A. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. Can Med Assoc J 2012, 184(12):E675-E683.
10. Colmers I.N., Bowker S.L., Johnson J.A. Thiazolidinedione use and cancer incidence in type 2 diabetes: A systematic review and meta-analysis. Diabetes Metab 2012, [Epub Oct]. 10.1016/j.diabet.2012.06.003.
11. Currie C.J., Poole C.D., Gale E.A.M. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009, 52:1766-1777.
12. Jonasson J.M., Ljung R., Talbäck M., Haglund B., Gudbjörnsdòttir S., Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009, 52:1745-1754.
13. Colhoun H.M., Epidemiology S.D.R.N. Group Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009, 52:1755-1765.
14. Hemkens L.G., Grouven U., Bender R., Günster C., Gutschmidt S., Selke G.W., et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009, 52:1732-1744.
15. Home P.D., Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009, 52:2499-2506.
16. Dejgaard A., Lynggaard H., Råstam J., Krogsgaard Thomsen M. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia 2009, 52:2507-2512.
17. Deeks J., Higgins J., Altman D. Analysing data and undertaking meta-analyses. Cochrane handbook for systematic reviews of interventions 2008, John Wiley & Sons, Ltd, Chichester, UK. J. Higgins, S. Green (Eds.).
18. Higgins J., Altman D. Addressing reporting biases. Cochrane handbook for systematic reviews of interventions 2008, John Wiley & Sons, Ltd, Chichester, UK. Higgins J., Green S. (Eds.).
19. Campbell P.T., Deka A., Jacobs E.J., Newton C.C., Hildebrand J.S., McCullough M.L., et al. Prospective study reveals associations between colorectal cancer and type 2 diabetes mellitus or insulin use in men. Gastroenterology 2010, 139:1138-1146.
20. Carstensen B., Witte D.R., Friis S. Cancer occurrence in Danish diabetic patients: duration and insulin effects. Diabetologia 2012, 55:948-958.
21. Chang C.H., Toh S., Lin J.W., Chen S.T., Kuo C.W., Chuang L.M., et al. Cancer risk associated with insulin glargine among adult type 2 diabetes patients - a nationwide cohort study. PLoS ONE 2011, 6:e21368.
22. Lai S.W., Liao K.F., Chen P.C., Tsai P.Y., Hsieh D.P.H., Chen C.C. Antidiabetes drugs correlate with decreased risk of lung cancer: a population-based observation in Taiwan. Clin Lung Cancer 2012, 13:143-148.
23. Libby G., Donnelly L.A., Donnan P.T., Alessi D.R., Morris A.D., Evans J.M.M. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009, 32:1620-1625.
24. Ljung R., Talbäck M., Haglund B., Jonasson J.M., Gudbjörnsdòttir S., Steineck G. Insulin glargine use and short-term incidence of malignancies - a three-year population-based observation. Acta Oncologica 2011, 50:685-693.
25. Monami M., Lamanna C., Pala L., Bardini G., Cresci B., Francesconi P., et al. Treatment with insulin secretagogues and cancer-related mortality in type 2 diabetic patients a retrospective cohort study. Exp Clin Endocrinol Diabetes 2008, 116(3):184-189.
26. Oliveria S.A., Koro C., Ulcickas Yood M., Sowell M. Cancer incidence among patients treated with antidiabetic therapy. Diabetes Metab Syndr 2008, 2:45-57.
27. Ruiter R., Visser L.E., van Herk-Sukel M.P.P., Coebergh J.W.W., Haak H.R., Geelhoed-Duijvestijn P.H., et al. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia 2012, 55:51-62.
28. Suissa S., Azoulay L., Dell'aniello S., Evans M., Vora J., Pollak M. Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia 2011, 54:2254-2262.
29. Yang X., Ko G.T., So W.Y., Ma R.C.W., Yu L.W.L., Kong A.P.S., et al. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes 2010, 59:1254-1260.
30. Yang Y.X., Hennessy S., Lewis J.D. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 2004, 127:1044-1050.
31. Bodmer M., Meier C., Krähenbühl S., Jick S.S., Meier C.R. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010, 33:1304-1308.
32. Chung Y.W., Han D.S., Park K.H., Eun C.S., Yoo K.S., Park C.K. Insulin therapy and colorectal adenoma risk among patients with Type 2 diabetes mellitus: a case-control study in Korea. Dis Colon Rectum 2008, 51:593-597.
33. Koro C., Barrett S., Qizilbash N. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol Drug Saf 2007, 16:485-492.
34. Mannucci E., Monami M., Balzi D., Cresci B., Pala L., Melani C., et al. Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2010, 33:1997-2003.
35. Belfiore A., Malaguarnera R. Insulin receptor and cancer. Endocr Relat Cancer 2011, 18:R125-R147.
36. Kurtzhals P., Schäffer L., Sørensen A., Kristensen C., Jonassen I., Schmid C., et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000, 49:999-1005.
37. Zeng H., Datta K., Neid M., Li J., Parangi S., Mukhopadhyay D. Requirement of different signaling pathways mediated by insulin-like growth factor-I receptor for proliferation, invasion, and VPF/VEGF expression in a pancreatic carcinoma cell line. Biochem Biophys Res Commun 2003, 302:46-55.
38. Ben Q., Xu M., Ning X., Liu J., Hong S., Huang W., et al. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer 2011, 47:1928-1937.
39. Johnson J.A., Bowker S.L., Richardson K., Marra C.A. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia 2011, 54:2263-2271.
40. Magruder J.T., Elahi D., Andersen D.K. Diabetes and pancreatic cancer: chicken or egg?. Pancreas 2011, 40:339-351.
41. Kasper J.S., Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidem Biomar 2006, 15:2056-2062.
42. Hong S.K., Oh J.J., Byun S.S., Hwang S.I., Lee H.J., Choe G., et al. Impact of diabetes mellitus on the detection of prostate cancer via contemporary multi (≥12)-core prostate biopsy. Prostate 2012, 72:51-57.
43. Simon D., Charles M.A., Lahlou N., Nahoul K., Oppert J.M., Gouault-Heilmann M., et al. Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone: a 3-month randomized placebo-controlled trial. Diabetes Care 2001, 24:2149-2151.
44. Frayling T.M., Colhoun H., Florez J.C. A genetic link between type 2 diabetes and prostate cancer. Diabetologia 2008, 51:1757-1760.
45. Ray W.A. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003, 158:915-920.
46. Papanikolaou P.N., Christidi G.D., Ioannidis J.P.A. Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ 2006, 174:635-641.
47. Vandenbroucke J.P. Why do the results of randomised and observational studies differ?. BMJ 2011, 343:d7020.
48. Inzucchi S.E., Sherwin R.S. The prevention of type 2 diabetes mellitus. Endocrinol Metab Clin North Am 2005, 34:199-219.
49. de Vries F., de Vries C., Cooper C., Leufkens B., van Staa T.P. Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database. Int J Epidemiol 2006, 35:1301-1308.
50. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008, 167:492-499.